Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 52Plasma cell 43Other hematologic neoplasm 35Myeloid 12Sarcoma 6CNS 5Gastrointestinal 3Dermatologic 2Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Pancreatic Neoplasms 3Ovarian Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
plerixafor × Gastrointestinal × Clear all
NCT04177810 2024-02-23

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
25 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT03277209 2020-03-02

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Weill Medical College of Cornell University

Phase 1 Terminated
2 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02179970 2019-07-23

CAM-PLEX

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed
26 enrolled
GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡